Prevention of type 2 diabetes in Germany. Ideas - evidence - implementation;Prävention des typ-2-diabetes in Deutschland. Von der idee über die evidenz zur implementierung

Medizinische Klinik

Volumn 101, Issue 9, 2006, Pages 730-736

  Schwarz, Peter E H ^a,b   Schuppenies, Andrea ^a   Gruhl, Ulrike ^b   Hoffmann, Reinhart ^c   Bornstein, Stefan R ^a   Schulze, Jan ^a   Landgraf, Rüdiger ^b  

^a UNIVERSITY HOSPITAL CARL GUSTAV CARUS   (Germany)

^b Nationales Aktionsforum Diabetes Mellitus   (Germany)

^c Deutsche Diabetes Stiftung   (Germany)

Author keywords

Guideline; Implementation; Prevention; Three step model; Type 2 diabetes

Indexed keywords

DIET; EXERCISE; GERMANY; HUMAN; IMPAIRED GLUCOSE TOLERANCE; LIFESTYLE; MOTIVATION; NON INSULIN DEPENDENT DIABETES MELLITUS; PRACTICE GUIDELINE; QUALITY CONTROL; REVIEW;

CROSS-SECTIONAL STUDIES; DIABETES MELLITUS, TYPE 2; EVIDENCE-BASED MEDICINE; EXERCISE; FOOD HABITS; GERMANY; HEALTH PLAN IMPLEMENTATION; HUMANS; LIFE STYLE; NATIONAL HEALTH PROGRAMS; PRACTICE GUIDELINES; PRACTICE GUIDELINES AS TOPIC; PREDIABETIC STATE; QUALITY ASSURANCE, HEALTH CARE; RISK FACTORS; WEIGHT LOSS;

EID: 33748932888     PISSN: 07235003     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00063-006-1100-2     Document Type: Review

References (30)

1. Knowler WC, et al. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med 2002;346:393-403.
2. Tuomilehto J, et al. Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance. N Engl J Med 2001;344:1343-50.
3. Chiasson JL, et al. Acarbose for prevention of type 2 diabetes mellitus: the STOP-NIDDM randomised trial. Lancet 2002;359:2072-7.
4. Pan XR, et al. Effects of diet and exercise in preventing NIDDM in people with impaired glucose tolerance. The Da Qing IGT and Diabetes Study. Diabetes Care 1997;20:537-44.
5. Lindstrom J, Tuomilehto J. The Diabetes Risk Score: a practical tool to predict type 2 diabetes risk. Diabetes Care 2003;26:725-31.
6. Torgerson JS, et al. XENical in the prevention of Diabetes in Obese Subjects (XENDOS) study: a randomized study of orlistat as an adjunct to lifestyle changes for the prevention of type 2 diabetes in obese patients. Diabetes Care 2004;27:155-61.
7. Ramachandran A, et al. The Indian Diabetes Prevention Programme shows that lifestyle modification and metformin prevent type 2 diabetes in Asian Indian subjects with impaired glucose tolerance (IDPP-1). Diabetologia 2006;49:289-97.
8. Valensi P, et al. Pre-diabetes essential action: a European perspective. Diabetes Metab 2005;31:606-20.
9. Schneider H, Lischinski M, Jutzi E. [Prognosis of diabetic patients in Northeast Germany.] Z Ärztl Fortbild (Jena) 1994;88:925-30.
10. Narayan KM, et al. Lifetime risk for diabetes mellitus in the United States. JAMA 2003;290:1884-90.
11. Liebl A, et al. [Costly type 2 diabetes mellitus. Does diabetes cost 20 billion per year?] MMW Fortschr Med 2000;142:39-42.
12. UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 1998;352:837-53.
13. UK Prospective Diabetes Study (UKPDS). XI: Biochemical risk factors in type 2 diabetic patients at diagnosis compared with age-matched normal subjects. Diabet Med 1994;11:534-44.
14. Haffner SM, et al. Insulin-resistant prediabetic subjects have more atherogenic risk factors than insulin-sensitive prediabetic subjects: implications for preventing coronary heart disease during the prediabetic state. Circulation 2000;101:975-80.
15. Fontbonne A, et al. Body fat distribution and coronary heart disease mortality in subjects with impaired glucose tolerance or diabetes mellitus: the Paris Prospective Study, 15-year follow-up. Diabetologia 1992;35:464-8.
16. Fagot-Campagna A, Narayan KM, Imperatore G. Type 2 diabetes in children. BMJ 2001;322:377-8.
17. Statement of the American Diabetes Association. Within-trial cost-effectiveness of lifestyle intervention or metformin for the primary prevention of type 2 diabetes. Diabetes Care 2003;26:2518-23.
18. Zimmet P, Shaw J, Alberti KG. Preventing type 2 diabetes and the dysmetabolic syndrome in the real world: a realistic view. Diabet Med 2003;20:693-702.
19. Schwarz P, et al. Prevention of type 2 diabetes: what challenges do we have to address? J Public Health 2005;2:296-303.
20. Schwarz P, et al. Gründung der "Arbeitsgemeinschaft Prävention des Typ-2-Diabetes" der DDG. Diabetes Stoffw 2003;12:269-73.
21. Hauner H, et al. [Prevention of type 2 diabetes mellitus. Position paper of the National Action Forum for Diabetes Mellitus.] Dtsch Med Wochenschr 2005;130:1053-4.
22. Schwarz P. Risikoerkennung zur Prävention des Diabetes mellitus Typ 2. Diabetes aktuell für die Hausarztpraxis 2005;2:5-8.
23. Anderson KM, et al. An updated coronary risk profile. A statement for health professionals. Circulation 1991;83:356-62.
24. Assmann G, Cullen P, Schulte H. Simple scoring scheme for calculating the risk ot acute coronary events based on the 10-year follow-up of the PROspective CArdiovascular Munster (PROCAM) study. Circulation 2002;105:310-5.
25. Saaristo T, et al. Cross-sectional evaluation of the Finnish Diabetes Risk Score: a tool to identify undetected type 2 diabetes, abnormal glucose tolerance and metabolic syndrome. Diab Vasc Dis Res 2005;2:67-72.
26. Silventoinen K, et al. The validity of the Finnish Diabetes Risk Score for the prediction of the incidence of coronary heart disease and stroke, and total mortality. Eur J Cardiovasc Prev Rehabil 2005;12:451-8.
27. Glumer C, et al. A Danish diabetes risk score for targeted screening: the Inter99 study. Diabetes Care 2004;27:727-33.
28. Schwarz P. [Targeted diabetes prevention in high risk groups: pro.] Dtsch Med Wochenschr 2005;130:1103.
29. Weber I, et al. Mehr Evidenz - breitere Akzeptanz - erhöhte Chancen auf Umsetzung einer Maßnahme zur Prävention des Typ 2-Diabetes in Deutschland. In: Gesellschaft für Versicherungswissenschaft und -gestaltung e.V., Hrsg. gesundheitsziele.de 2005. Berlin: Gesellschaft für Versicherungswissenschaft und -gestaltung e.V., 2005:239-45.
30. Schulze J, et al. [Improvement of care for diabetics using the care model from Saxony.] Dtsch Med Wochenschr 2003;128:1161-6.